Immunotherapy of lethal metastases by lymphocytes sensitized against tumor cells in vitro

Area of Science:

• Immunology
• Oncology
• Cancer Research

Background:

• Tumor metastasis remains a primary cause of cancer-related mortality.
• The potential of the immune system to prevent cancer metastasis is an area of active investigation.
• Developing effective immunotherapies to combat metastatic disease is a critical goal in cancer treatment.

Purpose of the Study:

• To investigate whether the immune system can prevent tumor metastasis.
• To evaluate the efficacy of in vitro sensitized syngeneic lymphocytes as a therapeutic strategy against spontaneous lung metastases.
• To establish a preclinical model for assessing immunotherapy in preventing lethal metastatic disease.

Main Methods:

• A mouse model was established using subcutaneous tumor cells that spontaneously metastasized to the lungs.
• Local tumors were surgically excised.
• Mice were subsequently inoculated with syngeneic lymphocytes sensitized against tumor cells in vitro.
• Survival rates were monitored as the primary endpoint to assess the prevention of death by lung metastases.

Main Results:

• Mice receiving control treatment showed survival rates of approximately 30-40%.
• Mice treated with in vitro sensitized lymphocytes demonstrated significantly improved survival, with approximately 70% surviving.
• The immunotherapy effectively prevented the development of lethal lung metastases.

Conclusions:

• Sensitization of syngeneic lymphocytes against tumor cells in vitro, followed by their administration after local tumor removal, can prevent lethal metastases.
• This immunotherapy approach holds promise for preventing the spread of cancer and improving patient outcomes.
• The study validates the role of immune system modulation in controlling metastatic cancer progression.